An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment

by Meletios A. Dimopoulos, Joseph Mikhael, Evangelos Terpos, Xavier Leleu, Philippe Moreau, Joan Bladé, Jin Seok Kim, Keith Stockerl-Goldstein, Paul G. Richardson
Published 2022-04-01

Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia

by Ramzi Abboud, Ezhilarasi Chendamarai, Michael P. Rettig, Kathryn M. Trinkaus, Peter A. Riedell, Camille N. Abboud, Armin Ghobadi, Iskra Pusic, Keith Stockerl-Goldstein, Mark A. Schroeder, Ravi Vij, Peter Westervelt, John F. DiPersio, Geoffrey L. Uy
Published 2020-08-01

PB2122: A PHASE 1/2 MULTI-CENTER, DOSE-FINDING STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PK AND EFFICACY OF ZN-D5, A NOVEL BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY...

by Efstathios Kastritis, Jeffrey Matous, Jesus Berdeja, Emad Abro, Bradley Augustson, Valentin Cabañas Perianes, M. Theresa Cibeira, Yael Cohen, Michael Fong, Moshe Gatt, Veronica Gonzalez DE LA Calle, Fiona Kwok, Noa Lavi, Hila Magen, Albert Oriol, Giovanni Palladini, Keith Stockerl-Goldstein, Taylor Eves, Cheng Zheng, Anthony Fiorino
Published 2023-08-01

Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma

by Dominik Dytfeld, Jagoda Jasielec, Kent A. Griffith, Daniel Lebovic, David H. Vesole, Sundar Jagannath, Ammar Al-Zoubi, Tara Anderson, Kristen Detweiler-Short, Keith Stockerl-Goldstein, Asra Ahmed, Terri Jobkar, Diane E. Durecki, Kathryn McDonnell, Melissa Mietzel, Daniel Couriel, Mark Kaminski, Ravi Vij, Andrzej J. Jakubowiak
Published 2014-09-01